FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205522073> ?p ?o ?g. }

• W3205522073 endingPage "S38" @default.
• W3205522073 startingPage "S38" @default.
• W3205522073 abstract "BACKGROUND The addition of low-dose rivaroxaban to aspirin in patients with stable atherosclerotic disease has been shown effective in reducing ischemic events. However, what proportion of cardiology patients might be deemed eligible for such therapy remains uncertain. We aimed to estimate the rate of eligibility among cardiology outpatients at an academic tertiary care center. METHODS AND RESULTS We retrospectively reviewed the antithrombotic treatment of all patients presenting to the cardiology clinic in an academic tertiary care center between January 1st to February 28th, 2019. Among patients with atherosclerotic disease, but without an indication for anticoagulation, we assessed the extent of atherosclerosis, recent ischemic events (myocardial infarction or cerebral vascular accident), ischemic risk factors (smoking, diabetes, dyslipidemia, history of stroke) and their eligibility for aspirin and low dose rivaroxaban combination therapy based on the inclusion criteria of the COMPASS trial. A total of 2503 unique patients consulted at the cardiology clinic during the period of study. Of these, 1172 patients (46.8%) had a diagnosis of atherosclerotic vascular disease, of whom 286 (24.4%) already received anticoagulation (TABLE). Among those without an indication for anticoagulation, 59 (6.7%) had no documented antithrombotic therapy, 616 (69.5%) patients were on ASA alone, and 46 (5.2%) were on P2Y12-inhibitor monotherapy. Of note, the coexistence of coronary and peripheral artery disease (often a criterion for formulary reimbursement) was documented in only 115 (13.0%) vascular disease patients without an indication for anticoagulation. CONCLUSION While a large proportion of cardiology outpatients could potentially benefit from the combination of ASA and low-dose rivaroxaban, the coexistence of coronary and peripheral vascular disease might be underdiagnosed. A combination of educational initiatives and targeted interventions might improve the identification of eligible patients and lead to better cardiovascular outcomes. Furthermore, given the bleeding risk associated with this drug combination, a shared decision making would also likely improve the quality of care. The addition of low-dose rivaroxaban to aspirin in patients with stable atherosclerotic disease has been shown effective in reducing ischemic events. However, what proportion of cardiology patients might be deemed eligible for such therapy remains uncertain. We aimed to estimate the rate of eligibility among cardiology outpatients at an academic tertiary care center. We retrospectively reviewed the antithrombotic treatment of all patients presenting to the cardiology clinic in an academic tertiary care center between January 1st to February 28th, 2019. Among patients with atherosclerotic disease, but without an indication for anticoagulation, we assessed the extent of atherosclerosis, recent ischemic events (myocardial infarction or cerebral vascular accident), ischemic risk factors (smoking, diabetes, dyslipidemia, history of stroke) and their eligibility for aspirin and low dose rivaroxaban combination therapy based on the inclusion criteria of the COMPASS trial. A total of 2503 unique patients consulted at the cardiology clinic during the period of study. Of these, 1172 patients (46.8%) had a diagnosis of atherosclerotic vascular disease, of whom 286 (24.4%) already received anticoagulation (TABLE). Among those without an indication for anticoagulation, 59 (6.7%) had no documented antithrombotic therapy, 616 (69.5%) patients were on ASA alone, and 46 (5.2%) were on P2Y12-inhibitor monotherapy. Of note, the coexistence of coronary and peripheral artery disease (often a criterion for formulary reimbursement) was documented in only 115 (13.0%) vascular disease patients without an indication for anticoagulation. While a large proportion of cardiology outpatients could potentially benefit from the combination of ASA and low-dose rivaroxaban, the coexistence of coronary and peripheral vascular disease might be underdiagnosed. A combination of educational initiatives and targeted interventions might improve the identification of eligible patients and lead to better cardiovascular outcomes. Furthermore, given the bleeding risk associated with this drug combination, a shared decision making would also likely improve the quality of care." @default.
• W3205522073 created "2021-10-25" @default.
• W3205522073 creator A5009608699 @default.
• W3205522073 creator A5013054661 @default.
• W3205522073 creator A5018673468 @default.
• W3205522073 creator A5028510733 @default.
• W3205522073 creator A5036120229 @default.
• W3205522073 creator A5040692250 @default.
• W3205522073 creator A5064416722 @default.
• W3205522073 creator A5069823270 @default.
• W3205522073 date "2021-10-01" @default.
• W3205522073 modified "2023-09-26" @default.
• W3205522073 title "ELIGIBILITY FOR ASPIRIN PLUS LOW-DOSE RIVAROXABAN AMONG CARDIOLOGY OUTPATIENTS IN AN ACADEMIC TERTIARY CARE CENTER" @default.
• W3205522073 doi "https://doi.org/10.1016/j.cjca.2021.07.081" @default.
• W3205522073 hasPublicationYear "2021" @default.
• W3205522073 type Work @default.
• W3205522073 sameAs 3205522073 @default.
• W3205522073 citedByCount "0" @default.
• W3205522073 crossrefType "journal-article" @default.
• W3205522073 hasAuthorship W3205522073A5009608699 @default.
• W3205522073 hasAuthorship W3205522073A5013054661 @default.
• W3205522073 hasAuthorship W3205522073A5018673468 @default.
• W3205522073 hasAuthorship W3205522073A5028510733 @default.
• W3205522073 hasAuthorship W3205522073A5036120229 @default.
• W3205522073 hasAuthorship W3205522073A5040692250 @default.
• W3205522073 hasAuthorship W3205522073A5064416722 @default.
• W3205522073 hasAuthorship W3205522073A5069823270 @default.
• W3205522073 hasConcept C126322002 @default.
• W3205522073 hasConcept C127413603 @default.
• W3205522073 hasConcept C164705383 @default.
• W3205522073 hasConcept C2776301958 @default.
• W3205522073 hasConcept C2777015399 @default.
• W3205522073 hasConcept C2777628954 @default.
• W3205522073 hasConcept C2778213512 @default.
• W3205522073 hasConcept C2778661090 @default.
• W3205522073 hasConcept C2779161974 @default.
• W3205522073 hasConcept C2780645631 @default.
• W3205522073 hasConcept C500558357 @default.
• W3205522073 hasConcept C71924100 @default.
• W3205522073 hasConcept C78519656 @default.
• W3205522073 hasConceptScore W3205522073C126322002 @default.
• W3205522073 hasConceptScore W3205522073C127413603 @default.
• W3205522073 hasConceptScore W3205522073C164705383 @default.
• W3205522073 hasConceptScore W3205522073C2776301958 @default.
• W3205522073 hasConceptScore W3205522073C2777015399 @default.
• W3205522073 hasConceptScore W3205522073C2777628954 @default.
• W3205522073 hasConceptScore W3205522073C2778213512 @default.
• W3205522073 hasConceptScore W3205522073C2778661090 @default.
• W3205522073 hasConceptScore W3205522073C2779161974 @default.
• W3205522073 hasConceptScore W3205522073C2780645631 @default.
• W3205522073 hasConceptScore W3205522073C500558357 @default.
• W3205522073 hasConceptScore W3205522073C71924100 @default.
• W3205522073 hasConceptScore W3205522073C78519656 @default.
• W3205522073 hasIssue "10" @default.
• W3205522073 hasLocation W32055220731 @default.
• W3205522073 hasOpenAccess W3205522073 @default.
• W3205522073 hasPrimaryLocation W32055220731 @default.
• W3205522073 hasRelatedWork W1972269502 @default.
• W3205522073 hasRelatedWork W2037180721 @default.
• W3205522073 hasRelatedWork W2038817894 @default.
• W3205522073 hasRelatedWork W2043890723 @default.
• W3205522073 hasRelatedWork W2081192620 @default.
• W3205522073 hasRelatedWork W2114891295 @default.
• W3205522073 hasRelatedWork W2134968660 @default.
• W3205522073 hasRelatedWork W2325909460 @default.
• W3205522073 hasRelatedWork W2397154677 @default.
• W3205522073 hasRelatedWork W2418235060 @default.
• W3205522073 hasVolume "37" @default.
• W3205522073 isParatext "false" @default.
• W3205522073 isRetracted "false" @default.
• W3205522073 magId "3205522073" @default.
• W3205522073 workType "article" @default.